Use of11C-PE2I PET in differential diagnosis of Parkinsonian disorders

Journal of Nuclear Medicine

Volumn 56, Issue 2, 2015, Pages 234-242

  Appel, Lieuwe ^a,b   Jonasson, My ^a,b   Danfors, Torsten ^a,b   Nyholm, Dag ^b   Askmark, Hakan ^b   Lubberink, Mark ^a,b   Sörensen, Jens ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

DAT; Dopamine transporter; Overall brain functional activity; Parkinsonism; PET; SPECT

Indexed keywords

CARBON 11; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; IOMETOPANE I 123; LEVODOPA; N [3 IODOPROP 2' ENYL] 2 BETA CARBOMETHOXY 3 BETA (4 METHYL PHENYL)NORTROPANE; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; TRACER; UNCLASSIFIED DRUG; CARBON; I123-PE2I; IOFLUPANE; NORTROPANE DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; BRAIN FUNCTION; CAUDATE NUCLEUS; CEREBELLUM; CEREBELLUM CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTAL GYRUS; GLUCOSE METABOLISM; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; IMAGE ANALYSIS; INFERIOR TEMPORAL CORTEX; INSULA; MALE; MESENCEPHALON; MOLECULAR IMAGING; MOTOR CORTEX; MOTOR DYSFUNCTION; ORBITAL CORTEX; PARIETAL CORTEX; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSENSORY CORTEX; THALAMUS; WHITE MATTER; AUTOMATION; DIAGNOSTIC USE; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONIAN DISORDERS; REPRODUCIBILITY; SCINTISCANNING;

AGED; AUTOMATION; CARBON RADIOISOTOPES; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NORTROPANES; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84922022134     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.148619     Document Type: Article

References (40)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
2. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing. 1999;28:99-102.
3. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123Iioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175-1182.
4. Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134:3146-3166.
5. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord. 2007;13(suppl 3):S425-S428.
6. Eckert T, Edwards C. The application of network mapping in differential diagnosis of Parkinsonian disorders. Clin Neurosci Res. 2007;6:359-366.
7. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med. 2010;51:596-609.
8. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443-450.
9. Kapucu OL, Nobili F, Varrone A, et al. EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2093-2102.
10. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14:783-801.
11. Eckert T, Feigin A, Lewis DE, Dhawan V, Frucht S, Eidelberg D. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord. 2007;22:167-173.
12. Teune LK, Bartels AL, de Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395-2404.
13. Nikolaus S, Antke C, Müller HW. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res. 2009;204:1-31.
14. Emond P, Guilloteau D, Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci Ther. 2008;14:47-64.
15. Emond P, Garreau L, Chalon S, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(49-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(39,49-disubstituted phenyl) nortropane: new high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40:1366-1372.
16. Ziebell M, Holm-Hansen S, Thomsen G, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51:1885-1891.
17. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57:229-238.
18. Ciumas C, Wahlin TB, Jucaite A, Lindstrom P, Halldin C, Savic I. Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy. Neurology. 2008;71:788-794.
19. DeLorenzo C, Lichenstein S, Schaefer K, et al. SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med. 2011;52:1150-1155.
20. Zheng M, Appel L, Luo F, et al. Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. Psychopharmacology (Berl). August 14, 2014 [Epub ahead of print].
21. Hirvonen J, Johansson J, Teräs M, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28:1059-1069.
22. DeLorenzo C, Kumar JSD, Zanderigo F, Mann JJ, Parsey RV. Modeling considerations for in vivo quantification of the dopamine transporter using [11C]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29: 1332-1345.
23. Jonasson M, Appel L, Engman J, et al. Validation of parametric methods for [11C]PE2I positron emission tomography. Neuroimage. 2013;74:172-178.
24. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
25. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287.
26. Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969-979.
27. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109-1118.
28. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1-9.
29. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33-39.
30. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54(suppl 5):S15-S19.
31. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872.
32. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-676.
33. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055-2066.
34. Meyer PT, Hellwig S, Amtage F. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393-400.
35. Gur RC, Ragland JD, Reivich M, Greenberg JH, Alavi A, Gur RE. Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state. Cereb Cortex. 2009;19:375-382.
36. Yaqub M, van Berckel BN, Schuitemaker A, et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[11C]PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32:1600-1608.
37. Varrone A, Asenbaum S, Vander Borght T, et al. European Association of Nuclear Medicine Neuroimaging Committee. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2010;36:2103-2110.
38. Ribeiro MJ, Ricard M, Lièvre MA, et al. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [11 C]PE2I in healthy volunteers. Nucl Med Biol. 2007;34:465-470.
39. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of Ldopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001;56:1559-1564.
40. Booij J, de Jong J, de Bruin K, et al. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359-366.